Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by Assuta Hospital Systems.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Maccabi
Information provided by:
Assuta Hospital Systems
ClinicalTrials.gov Identifier:
NCT00449345
First received: March 19, 2007
Last updated: May 28, 2007
Last verified: May 2007

March 19, 2007
May 28, 2007
May 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00449345 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
Not Provided

The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.

In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays.

In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers.

We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.

Not Provided
Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Latent Tuberculosis Infection
Procedure: Blood test for Quantiferon-GOLD assay
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
Not Provided
Not Provided

Inclusion Criteria:

  • Health care worker undergoing screening for LTBI

Exclusion Criteria:

  • Previous tuberculosis or treatment for LTBI
  • Immunosuppressed due to drug treatment, HIV, organ transplant
  • Recent TB contacts
Both
18 Years and older
Yes
Contact: David Shitrit, MD +972 8 946 8617 david_s@mac.org.il
Contact: Ben Fox, MRCP +972 8 946 8617 fox_b@mac.org.il
Israel
 
NCT00449345
2006055
No
Not Provided
Assuta Hospital Systems
Maccabi
Principal Investigator: David Shitrit, MD Maccabi Healthcare Services, Israel
Assuta Hospital Systems
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP